title: Factors associated with glucose metabolism disorders after kidney transplantation.
abstract: BACKGROUND
  Post-transplant diabetes mellitus (PTDM), pre-diabetes-impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are frequent complications after organ transplantation. The aim of this study was to assess the frequency of PTDM, IFG and IGT in a group of renal transplant recipients, to compare the frequency of glucose metabolism disorders in subjects treated with tacrolimus and with cyclosporine, and to establish the influence of different risk factors on the development of glucose metabolism disorders.
  
  
  METHODS
  We examined 206 non-diabetic kidney allograft recipients (age 46.4 ± 12.3 years, time since transplantation 45.5 ± ± 33.6 months, BMI 26.3 ± 4.5 kg/m2). Glucose metabolism disorders were diagnosed using an oral glucose tolerance test. Logistic regression was used to assess the influence of each risk factor (age, BMI, waist circumference, physical activity, the presence of cardiovascular disease, positive family history of diabetes, cholesterol and triglycerides concentration) on the development of glucose metabolism disorders.
  
  
  RESULTS
  In 103 patients (50%), we diagnosed glucose metabolism disorders. 19% of patients had PTDM, 14% IFG, and 17% IGT. We did not find any differences in the frequency of glucose metabolism disorders between patients treated with tacrolimus and with cyclosporine. Multivariate analysis identified BMI and a family history of diabetes as independent risk factors of glucose metabolism disorders.
  
  
  CONCLUSIONS
  We found a high prevalence of glucose metabolism disorders in the examined group. This suggests that kidney transplant recipients should be screened for these disturbances. Patients with higher BMI and with first-degree relatives with diabetes had an increased risk of glucose metabolism disorders after kidney transplantation.
authors: Department of Endocrinology and Diabetology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.
authors: Barbara
authors: B
authors: Brzezińska
authors: Roman
authors: R
authors: Junik
authors: Anna
authors: A
authors: Kamińska
authors: Zbigniew
authors: Z
authors: Włodarczyk
authors: Andrzej
authors: A
authors: Adamowicz
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015984:Causality; D015897:Comorbidity; D016572:Cyclosporine / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D044882:Glucose Metabolism Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D005951:Glucose Tolerance Test; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology; D050177:Overweight / Q000453:epidemiology; D011236:Prediabetic State / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D016559:Tacrolimus / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus